FRISSORA MARK P 4

What Happened
Mark P. Frissora, a director of BioAdapTives, received 4,808 shares of Series D Convertible Preferred Stock on May 1, 2026. The shares were issued as compensation for board services and reported on a Form 4 filed May 5, 2026. The reported acquisition price is $0.00 because the shares were issued as compensation (derivative award), not bought.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (appears later than the typical 2-business-day filing window).
• Transaction type: Other acquisition (code J) — issuance of Series D convertible preferred stock as compensation.
• Amount: 4,808 shares of Series D Convertible Preferred Stock; reported price $0.00.
• Conversion mechanics (from footnote): each Series D preferred share converts into 100 shares of common stock (i.e., 4,808 preferred → potential 480,800 common shares), subject to a 4.9% beneficial ownership limitation and a six‑month delay before conversion is allowed (except upon liquidation). Each preferred share carries 100 votes at stockholder meetings.
• Shares owned after the transaction: not specified in the filing.

Context
This was an equity award for board service, not an open‑market buy or sale. Such compensation is common for directors and does not, by itself, indicate a buy/sell signal. Because the preferred shares have conversion limits and a conversion waiting period, they are not immediately equivalent to common shares for trading or ownership percentage purposes.